Pasritamig

DRUG6 trials

Sponsors

Janssen Research & Development, LLC, Fred Hutchinson Cancer Center, GI Innovation, Inc.

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate NeoplasmsMetastatic Castration-resistant Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate CancerProstate CancerProstatic NeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

RecruitingNCT05818683

Janssen Research & Development, LLCMetastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

Start: 2023-04-26End: 2028-05-23Target: 300Updated: 2026-09-25

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

RecruitingNCT07319871

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2026-01-14End: 2027-04-30Target: 40Updated: 2026-09-25

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

Not yet recruitingNCT07860255

Fred Hutchinson Cancer CenterProstate Cancer

Start: 2026-11-30End: 2028-11-30Target: 18Updated: 2026-10-06

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

RecruitingNCT07871435

GI Innovation, Inc.Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start: 2026-10-12End: 2029-09-30Target: 107Updated: 2026-10-19

Phase 3

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

RecruitingNCT07164443

Janssen Research & Development, LLCMetastatic Castration-resistant Prostatic Neoplasms

Start: 2025-09-02End: 2028-08-18Target: 1203Updated: 2026-09-25

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT07225946

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2025-12-19End: 2030-06-07Target: 800Updated: 2026-09-25

Related Papers

A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2026-05-28

A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2026-05-28